Loading...

Skip to main content

Call us on + 1 (800) 604-9114 for more information about our products

Looking for specific datasheet Manual/COA/MSDS?
Request a Manual/COA/MSDS

Interested to get a quote about our products?
Request a Quote

ELISA (EIA) (Binding curve of anti-COVID-19 & SARS-CoV S glycoprotein antibody CR3022 to SARS-CoV-2 Spike Glycoprotein (S1), Sheep Fc-Tag and SARS-CoV-2 Spike Glycoprotein (S2), Sheep Fc-Tag from HEK293 cells. ELISA plate coated with SARS-CoV-2 Spike Glycoprotein (S1), Sheep Fc-Tag (blue line) or SARS-CoV-2 Spike Glycoprotein (S2), Sheep Fc-Tag (orange line) from HEK293 cells (The Native Antigen Company) at concentrations of 5 ug/ml. A 3-fold serial dilution from 125 ng/ml was performed. For detection, a 1:4000 dilution of HRP-labelled anti-human IgG antibody was used.)

COVID 19 Spike S glycoprotein Coronavirus Recombinant Antibody | COVID-19 recombinant antibody

Anti-COVID-19 & SARS-CoV S glycoprotein [CR3022], Rabbit IgG, Kappa

Reactivity
SARS-CoV-2 (COVID-19) & SARS Coronavirus
Applications
ELISA
Purity
Protein A affinity purified
Synonyms
COVID 19 Spike S glycoprotein Coronavirus; Monoclonal Recombinant Antibody; Anti-COVID-19 & SARS-CoV S glycoprotein [CR3022]; Rabbit IgG; Kappa; 2019 Novel Coronavirus; Coronavirus; CoV; COVID-19 virus; HCoV-2; Human Coronavirus 2019; SARS2; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Spike S glycoprotein; COVID-19 recombinant antibody
Ordering
For Research Use Only!
Reactivity
SARS-CoV-2 (COVID-19) & SARS Coronavirus
Clonality
Monoclonal
Isotype
Rabbit IgG
Clone Number
CR3022
Specificity
This antibody binds the amino acids 318-510 in the S1 domain of the SARS-CoV Spike protein as well as SARS-CoV-2 (COVID-19) Spike protein. The antibody also binds to P462L-substituted S318–510 fragments of the SARS spike protein. The binding epitope is only accessible in the "open" confromation of the spike protein (Joyce et al. 2020)
Purity/Purification
Protein A affinity purified
Form/Format
PBS with 0.02% Proclin 300.
Concentration
1 mg/ml (varies by lot)
Applicable Applications for COVID-19 recombinant antibody
Crystallography, NTRL, SPR, ELISA (EIA)
Application Notes
This antibody binds to both SARS-CoV and SARS-CoV-2 with high affinity (PMID: 16796401 & 32065055). The initial characterization of the binding of this antibody was performed by ELISA and indicates potential for the development of identification assays, as both virus-capture assays, or as controls in serological assays measuring immune-responses to virus exposure. Human IgG1, IgG3, IgM and IgA isotypes are available to mimic antibody responses seen in COVID19 (Amanat et al. 2020). Human IgG2 and IgG4 subtypes, which are also seen in a small subset of COVID-19 patients, are also available to investigate their role in the response to SARS-CoV-2. The original human IgG1 version of the antibody works synergistically in combination with another non-ompeting SARS antibody CR3014 and is a potential candidate for passive immune prophylaxis of SARS-CoV infection (Meulen et al., 2006). The original antibody (human IgG1) was also reported to bind the 2019-nCoV RBD (KD of 6.3 nM). This antibody has been attributed a potential to be developed as a therapeutic agent, alone or in combination with other neutralizing antibodies for treatment of 2019-nCoV infections (Tian et al., 2020).
Immunogen
The original monoclonal antibody was generated by sequencing peripheral blood lymphocytes of a patient exposed to the SARS-CoV.
Note
Clone CR3022 is available in human IgG1 (MBS488488) and rabbit IgG (MBS488489) isotype formats. The chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.
Preparation and Storage
Store at 4 degree C for up to 3 months. For longer storage, aliquot and store at -20 degree C.

ELISA (EIA)

(Binding curve of anti-COVID-19 & SARS-CoV S glycoprotein antibody CR3022 to SARS-CoV-2 Spike Glycoprotein (S1), Sheep Fc-Tag and SARS-CoV-2 Spike Glycoprotein (S2), Sheep Fc-Tag from HEK293 cells. ELISA plate coated with SARS-CoV-2 Spike Glycoprotein (S1), Sheep Fc-Tag (blue line) or SARS-CoV-2 Spike Glycoprotein (S2), Sheep Fc-Tag (orange line) from HEK293 cells (The Native Antigen Company) at concentrations of 5 ug/ml. A 3-fold serial dilution from 125 ng/ml was performed. For detection, a 1:4000 dilution of HRP-labelled anti-human IgG antibody was used.)

ELISA (EIA) (Binding curve of anti-COVID-19 & SARS-CoV S glycoprotein antibody CR3022 to SARS-CoV-2 Spike Glycoprotein (S1), Sheep Fc-Tag and SARS-CoV-2 Spike Glycoprotein (S2), Sheep Fc-Tag from HEK293 cells. ELISA plate coated with SARS-CoV-2 Spike Glycoprotein (S1), Sheep Fc-Tag (blue line) or SARS-CoV-2 Spike Glycoprotein (S2), Sheep Fc-Tag (orange line) from HEK293 cells (The Native Antigen Company) at concentrations of 5 ug/ml. A 3-fold serial dilution from 125 ng/ml was performed. For detection, a 1:4000 dilution of HRP-labelled anti-human IgG antibody was used.)

ELISA (EIA)

(Binding curve of anti-COVID-19 & SARS-CoV S glycoprotein antibody CR3022 to SARS-CoV-2 Spike Glycoprotein domains S1 and S2 of various origin. ELISA plate coated with SARS-CoV-2 Spike Glycoprotein (S1), His-Tag (Insect Cells; grey line), SARS-CoV-2 Spike Glycoprotein (S2), His-Tag (Insect Cells; yellow line) and SARS Coronavirus Spike Glycoprotein (S1), His-Tag (HEK293 cells; blue line) (The Native Antigen Company) at concentrations of 5 ug/ml. A 3-fold serial dilution from 41.6 ng/ml was performed. For detection, a 1:4000 dilution of HRP-labelled anti-human IgG antibody was used.)

ELISA (EIA) (Binding curve of anti-COVID-19 & SARS-CoV S glycoprotein antibody CR3022 to SARS-CoV-2 Spike Glycoprotein domains S1 and S2 of various origin. ELISA plate coated with SARS-CoV-2 Spike Glycoprotein (S1), His-Tag (Insect Cells; grey line), SARS-CoV-2 Spike Glycoprotein (S2), His-Tag (Insect Cells; yellow line) and SARS Coronavirus Spike Glycoprotein (S1), His-Tag (HEK293 cells; blue line) (The Native Antigen Company) at concentrations of 5 ug/ml. A 3-fold serial dilution from 41.6 ng/ml was performed. For detection, a 1:4000 dilution of HRP-labelled anti-human IgG antibody was used.)

ELISA (EIA)

(Binding curve of four different formats of anti-COVID-19 & SARS-CoV S glycoprotein antibody CR3022 to SARS-CoV-2 Spike Glycoprotein domains S1 and S2 (His-Tag (Insect Cells)). ELISA plate coated with SARS-CoV-2 Spike Glycoprotein (S1), His-Tag (Insect Cells; grey line) and SARS-CoV-2 Spike Glycoprotein (S2), His-Tag (Insect Cells; yellow line) (Native Antigen) at concentrations of 5 ug/ml. A 3-fold serial dilution from 41.6 ng/ml was performed; from 370 ng/ml and from 10000 ng/ml. Human IgM, human IgA and human IgG2 were HRP-conjugated and for the detection of human IgG1 a 1:4000 dilution of HRP-labelled anti-human IgG antibody was used.)

ELISA (EIA) (Binding curve of four different formats of anti-COVID-19 & SARS-CoV S glycoprotein antibody CR3022 to SARS-CoV-2 Spike Glycoprotein domains S1 and S2 (His-Tag (Insect Cells)). ELISA plate coated with SARS-CoV-2 Spike Glycoprotein (S1), His-Tag (Insect Cells; grey line) and SARS-CoV-2 Spike Glycoprotein (S2), His-Tag (Insect Cells; yellow line) (Native Antigen) at concentrations of 5 ug/ml. A 3-fold serial dilution from 41.6 ng/ml was performed; from 370 ng/ml and from 10000 ng/ml. Human IgM, human IgA and human IgG2 were HRP-conjugated and for the detection of human IgG1 a 1:4000 dilution of HRP-labelled anti-human IgG antibody was used.)
Related Product Information for COVID-19 recombinant antibody
Recombinant monoclonal antibody to COVID-19 & SARS-CoV S glycoprotein. Manufactured using Recombinant Platform with variable regions (i.e. specificity) from the B-cell clone CR3022.
References
Meulen et al. Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants PLoS Med. 2006 Jul; 3(7): e237 PMID:16796401

NCBI and Uniprot Product Information

UniProt Accession #

Similar Products

Product Notes

The COVID-19 (Catalog #AAA488489) is a Recombinant Antibody and is intended for research purposes only. The product is available for immediate purchase. The Anti-COVID-19 & SARS-CoV S glycoprotein [CR3022], Rabbit IgG, Kappa reacts with SARS-CoV-2 (COVID-19) & SARS Coronavirus and may cross-react with other species as described in the data sheet. AAA Biotech's COVID 19 Spike S glycoprotein Coronavirus can be used in a range of immunoassay formats including, but not limited to, Crystallography, NTRL, SPR, ELISA (EIA). This antibody binds to both SARS-CoV and SARS-CoV-2 with high affinity (PMID: 16796401 & 32065055). The initial characterization of the binding of this antibody was performed by ELISA and indicates potential for the development of identification assays, as both virus-capture assays, or as controls in serological assays measuring immune-responses to virus exposure. Human IgG1, IgG3, IgM and IgA isotypes are available to mimic antibody responses seen in COVID19 (Amanat et al. 2020). Human IgG2 and IgG4 subtypes, which are also seen in a small subset of COVID-19 patients, are also available to investigate their role in the response to SARS-CoV-2. The original human IgG1 version of the antibody works synergistically in combination with another non-ompeting SARS antibody CR3014 and is a potential candidate for passive immune prophylaxis of SARS-CoV infection (Meulen et al., 2006). The original antibody (human IgG1) was also reported to bind the 2019-nCoV RBD (KD of 6.3 nM). This antibody has been attributed a potential to be developed as a therapeutic agent, alone or in combination with other neutralizing antibodies for treatment of 2019-nCoV infections (Tian et al., 2020). Researchers should empirically determine the suitability of the COVID-19 for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. It is sometimes possible for the material contained within the vial of "COVID 19 Spike S glycoprotein Coronavirus, Monoclonal Recombinant Antibody" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.

Precautions

All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.

Disclaimer

Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.

Item has been added to Shopping Cart

If you are ready to order, navigate to Shopping Cart and get ready to checkout.

Looking for a specific manual?
Request a Manual

Request more Information

Please complete the form below and a representative will contact you as soon as possible.

Request a Manual

Please complete the form below and a representative will contact you as soon as possible.

Request a Quote

Please complete the form below and a representative will contact you as soon as possible.